Cargando…

Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis

Whether Mineralocorticoid receptor antagonists (MRA) reduce mortality and cardiovascular effects of dialysis patients remains unclear. A meta-analysis was designed to investigate whether MRA reduce mortality and cardiovascular effects of dialysis patients, with a registration in INPLASY (INPLASY2020...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gou, Wen-Jun, Zhou, Fa-Wei, Providencia, Rui, Wang, Bo, Zhang, Heng, Hu, Shou-Liang, Gao, Xiao-Li, Tuo, Yan-hong, Zhang, Yong, Li, Tian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152260/ https://www.ncbi.nlm.nih.gov/pubmed/35656294 http://dx.doi.org/10.3389/fphar.2022.823530

Ejemplares similares

Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease
por: Wu, Yichuan, et al.
Publicado: (2022)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2021)

The safety and efficacy of low-dose mineralocorticoid receptor antagonists in dialysis patients: A meta-analysis
por: Zhu, Yifan, et al.
Publicado: (2021)

Mineralocorticoid receptor antagonists in cardiovascular translational biology
por: Chilton, Robert J., et al.
Publicado: (2023)

The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury
por: Jaisser, Frédéric, et al.
Publicado: (2021)

Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
por: Funder, John W
Publicado: (2013)

Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis
por: Jiang, Xinrui, et al.
Publicado: (2022)

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
por: Orena, Stephen, et al.
Publicado: (2013)

Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
por: Palanisamy, Srikanth, et al.
Publicado: (2022)

Potential Impact of Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiovascular Disease
por: Rahman, Asadur, et al.
Publicado: (2023)

Why are mineralocorticoid receptor antagonists cardioprotective?
por: Chai, Wenxia, et al.
Publicado: (2006)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

Aldosterone Antagonists Reduce the Risk of Cardiovascular Mortality in Dialysis Patients: A Meta-Analysis
por: Li, Yan, et al.
Publicado: (2019)

Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis
por: Berbenetz, Nicolas M., et al.
Publicado: (2016)

Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy
por: Sun, Li‐Jing, et al.
Publicado: (2017)

The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic  Nephropathy
por: Goenka, Luxitaa, et al.
Publicado: (2019)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Vodošek Hojs, Nina, et al.
Publicado: (2021)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists
por: Mende, Christian W., et al.
Publicado: (2023)

Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis
por: Tesch, Greg H., et al.
Publicado: (2017)

Nonsteroidal Mineralocorticoid Receptor Antagonists and Protection Against Cardiovascular Disease in Patients with Diabetes Mellitus
por: Shimabukuro, Michio
Publicado: (2023)

Mineralocorticoid receptor antagonists for chronic heart failure: a meta-analysis focusing on the number needed to treat
por: Geng, Chang, et al.
Publicado: (2023)

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
por: Yugar-Toledo, Juan Carlos, et al.
Publicado: (2017)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
por: Baran, Wiktoria, et al.
Publicado: (2021)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Orexin, orexin receptor antagonists and central cardiovascular control
por: Carrive, Pascal
Publicado: (2013)

Mineralocorticoid Receptor Signaling in the Inflammatory Skeletal Muscle Microenvironments of Muscular Dystrophy and Acute Injury
por: Howard, Zachary M., et al.
Publicado: (2022)

A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis
por: Korol, Sandra, et al.
Publicado: (2017)

Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses
por: Felipe, Camila Q., et al.
Publicado: (2022)

Effects of mineralocorticoid receptor antagonists on responses to hemorrhagic shock in rats
por: Yamamoto, Kanako, et al.
Publicado: (2018)

Mineralocorticoid receptor antagonist use following heart failure hospitalization
por: Duran, Jason M., et al.
Publicado: (2020)

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
por: Tezuka, Yuta, et al.
Publicado: (2021)

Quality of Life of Primary Aldosteronism Patients by Mineralocorticoid Receptor Antagonists
por: Yoshida, Yuichi, et al.
Publicado: (2021)

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
por: Agarwal, Rajiv, et al.
Publicado: (2020)

Novel 1,4-Dihydropyridine Derivatives as Mineralocorticoid Receptor Antagonists
por: Pérez-Gordillo, Felipe Luis, et al.
Publicado: (2023)

Association between Mineralocorticoid Receptor Antagonist and Mortality in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis
por: Kim, Jean, et al.
Publicado: (2022)

Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!
por: Maiolino, Giuseppe, et al.
Publicado: (2015)

Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives
por: Vizzardi, Enrico, et al.
Publicado: (2014)

SAT-561 Effects of Mineralocorticoid Receptor Antagonists on Primary Aldosteronism Screening
por: Tezuka, Yuta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i1n87mk6t1ffm7n3iqut1e1tl0